

## **Biography and selected lithium publications per January 2017**

Rasmus W. Licht, M.D, Ph.D.

Aalborg University Hospital - Psychiatry  
Moelleparkvej 10  
9000 Aalborg  
Denmark

E-mail address: [RASMUS.LICHT@RN.DK](mailto:RASMUS.LICHT@RN.DK)

Cell phone: +45 40374350

Since 2013 Rasmus W. Licht has been a chair professor of psychiatry at Aalborg University and a chief psychiatrist at the Aalborg University Hospital and head of the Psychiatric Research Unit and research program there. Previously, he was a chief psychiatrist at the Aarhus University Hospital in Risskov through 20 years, where he established the first specialized clinic for the diagnosis and treatment of bipolar disorders in Denmark. At the same time he was an associated professor in psychiatry and an associated professor in clinical pharmacology at the University of Aarhus.

Since completing his training as a psychiatrist in 1992, Rasmus W. Licht has specialized in the psychopathological assessment and the psychopharmacological management of affective disorders. His research is focused on clinical epidemiology of affective disorders, including drug evaluation and trial methodology. In 1999 he finished his Ph.D. from the University of Aarhus with a thesis entitled: The validity of randomized controlled trials on antimanic drug effect – from clinical research to clinical practice. Rasmus W. Licht is active in national and international research networks. e.g. the Danish University Antidepressant Group (DUAG) and the international Group for the Study of Lithium (IGSLi).

Under the Danish Psychiatric Association, Rasmus W. Licht was the chairman of a subcommittee drawing up guidelines for the use of mood-stabilizers. He is also a member of the Steering Committee on Treatment Guidelines for Affective Disorders established under the World Federation of Societies of Biological Psychiatry, and he has co-authored several of these guidelines. Recently, he has contributed to national clinical guidelines on bipolar disorder developed by the Danish Board of Health.

Rasmus W. Licht has been the assistant to the editor in *Acta Psychiatrica Scandinavica* from 1998 to 2012 and a member of the editorial boards of several journals through the years, including *European Psychiatry* and *Pharmacopsychiatry*. He currently serves *Bipolar Disorders* and *The International Journal of Bipolar Disorders* as a board member. In addition he serves as a reviewer of other journals, e.g. the *American Journal of Psychiatry*, *Journal of Clinical Psychiatry*, *Journal of Affective Disorders, Depression and Anxiety*, *Lancet* and *JAMA Psychiatry*. He has published several original papers, review articles, editorials and book chapters.

Besides his research activities, Rasmus W. Licht is active in consulting and in passing on knowledge within his field of expertise at all levels, nationally and internationally.

He has served as an advisory board member for several pharmaceutical companies, nationally and internationally.

**Selected internationally published peer reviewed *lithium papers* (most recent appearing first)**

Kessing L.V., Gerds T.A., Feldt-Rasmussen B., Andersen P.K., Licht R.W. Lithium and renal and upper urinary tract tumors - results from a nationwide population-based study. *Bipolar Disorders* 2015: 17: 805-813.

Kessing L.V., Gerds T.A., Feldt-Rasmussen B., Andersen P.K., Licht R.W. Use of lithium and anticonvulsants and the rate of chronic kidney disease : a nationwide population-based study. *JAMA Psychiatry (Archives of General Psychiatry)* 2015: 72: 1182-1191.

Licht RW, Grabenhenrich LB, Nielsen RE, Berghofer A. Lithium and renal tumors: a critical comment to the report by Zaidan et al. *Kidney International* 2014: 86 :857

Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on long-term treatment of bipolar disorder. *World Journal of Biological Psychiatry* 2013: 14: 154-219.

Licht R. W. Lithium: still a major option in the management of bipolar disorder. *CNS Neuroscience & Therapeutics* 2012:18: 219-226.

Severus W.E., Lipkovich I.A., Licht,R.W., Young A.H., Greil W., Ketter T., Deberdt W., Tohen M. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. *European Psychiatry* 2010: 25: 443-449.

Licht,R.W., Nielsen J.N., Gram L.F. Vestergaard P. Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disoreder: an open, randomized effectiveness study mimicking clinical practice. The 6<sup>th</sup> trial of the Danish University Antidepressant Group (DUAG-6). *Bipolar Disorders* 2010: 12: 483-493.

Licht R.W. A new BALANCE in bipolar I disorder. *Lancet* 2010: 375: 350-352.

Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute bipolar depression. *World Journal of Biological.Psychiatry* 2010: 11: 81-109.

Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. *World Journal of Biological.Psychiatry* 2009: 10: 85-116.

Licht R.W., Vestergaard P, Brodersen A. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis: a complete 15-year register based follow-up. *Bipolar Disorders* 2008: 10: 79-86.

Tohen M., Greil W., Calabrese J.R., Sachs G.S., Yatham L.N., Oerlinghausen B.M., Koukopoulos A., Cassano G.B., Grunze H., Licht R.W., Dell'Osso L., Evans A.R., Risser R., Baker R.W., Crane H., Dossenbach M.R., Bowden C.L.. Olanzapine versus lithium in relapse/recurrence prevention in Bipolar disorder: a randomised double-blind controlled 12 month clinical trial. *American Journal of Psychiatry* 2005: 162: 1281-1290.

Licht R.W., Larsen J.O., Smith D. Brændgård H: Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellum. *European Neuropsychopharmacology* 2003: 13: 173-176.

Licht R.W., Vestergaard P., Rasmussen N.-A. and co-workers: A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. *Acta Psychiatrica Scandinavica* 2001: 104: 387-390.

Brodersen A., Licht R.W., Vestergaard P, Olesen A., Mortensen PB: 16-year mortality in lithium-treated affective disorder patients. *British Journal of Psychiatry* 2000: 176: 429-433.

Licht R.W.: Drug treatment of mania: a critical review. *Acta Psychiatrica Scandinavica* 1998: 97: 387-397.

Vestergaard P., Licht R.W., Brodersen A. and co-workers: Comparison of two serum lithium levels for prophylactic treatment of affective disorders. *Acta Psychiatrica Scandinavica* 1998: 98: 310-315.

Licht R.W., Gouliaev G., Vestergaard P. and Frydenberg M.: Generalizability of results from randomized drug trials, exemplified by a trial on antimanic treatment. *British Journal of Psychiatry* 1997: 170: 264-267.

Licht R.W., Smith D., Brændgård H.: The effect of chronic lithium treatment on the caliber of the sural nerve in rats. *European Neuropsychopharmacology* 1997: 7: 95-98.

Gouliaev G., Licht R.W., Vestergaard P., Lund H., Merinder L., Bjerre L.: Treatment of acute mania with lithium and clonazepam or zuclopenthixol and clonazepam. *Acta Psychiatrica Scandinavica* 1996: 93: 119-124.

Licht R.W., Larsen J.O., Brændgård H., Smith D.: The effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex. *Psychopharmacology* 1994: 115: 371-374.

Licht R.W., Gouliaev G., Vestergaard P., Lund H., Merinder L, Dybbro J.: Treatment of manic episodes in Scandinavia: the use of neuroleptics in a clinical routine setting. *Journal of Affective Disorders* 1994: 32: 179-185.